Tamara Minko

List of Publications by Year in descending order

71 papers	7,300 citations	57758 44 h-index	91884 69 g-index
71 all docs	71 docs citations	71 times ranked	8992 citing authors

#	Article	IF	Citations
1	Coâ€delivery of Doxorubicin and Bclâ€2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrugâ€Resistant Cancer Cells. Small, 2009, 5, 2673-2677.	10.0	613
2	Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Delivery and Translational Research, 2018, 8, 1483-1507.	5.8	350
3	Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. Journal of Controlled Release, 2013, 171, 349-357.	9.9	331
4	Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine, 2008, 3, 761-776.	3.3	316
5	Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. Journal of Controlled Release, 2009, 140, 284-293.	9.9	305
6	Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. Journal of Controlled Release, 2011, 153, 16-22.	9.9	294
7	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS Journal, 2021, 23, 14.	4.4	291
8	Nanotechnology approaches for inhalation treatment of lung diseases. Journal of Controlled Release, 2015, 219, 500-518.	9.9	258
9	Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?. Journal of Controlled Release, 2008, 130, 107-114.	9.9	218
10	Dendrimer Versus Linear Conjugate:Â Influence of Polymeric Architecture on the Delivery and Anticancer Effect of Paclitaxel. Bioconjugate Chemistry, 2006, 17, 1464-1472.	3.6	209
11	Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. Journal of Drug Targeting, 2011, 19, 900-914.	4.4	205
12	Internally Cationic Polyamidoamine PAMAM-OH Dendrimers for siRNA Delivery: Effect of the Degree of Quaternization and Cancer Targeting. Biomacromolecules, 2009, 10, 258-266.	5.4	202
13	Drug targeting to the colon with lectins and neoglycoconjugates. Advanced Drug Delivery Reviews, 2004, 56, 491-509.	13.7	197
14	Surface-Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery. Bioconjugate Chemistry, 2008, 19, 1396-1403.	3.6	196
15	Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing. ACS Nano, 2011, 5, 1877-1887.	14.6	184
16	Nanocarrier-based systems for targeted and site specific therapeutic delivery. Advanced Drug Delivery Reviews, 2019, 144, 57-77.	13.7	171
17	Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10737-10742.	7.1	162
18	Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug. Clinical Cancer Research, 2013, 19, 6193-6204.	7.0	149

#	Article	IF	Citations
19	Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense. Cancer Research, 2004, 64, 6214-6224.	0.9	147
20	Intratracheal Versus Intravenous Liposomal Delivery of siRNA, Antisense Oligonucleotides and Anticancer Drug. Pharmaceutical Research, 2009, 26, 382-394.	3.5	141
21	Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes. Current Drug Delivery, 2011, 8, 59-69.	1.6	137
22	Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Advanced Drug Delivery Reviews, 2013, 65, 1880-1895.	13.7	133
23	Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharmaceutical Research, 2003, 20, 351-359.	3.5	91
24	Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics, 2019, 9, 8362-8376.	10.0	90
25	Dendritic Silica Nanomaterials (KCC-1) with Fibrous Pore Structure Possess High DNA Adsorption Capacity and Effectively Deliver Genes In Vitro. Langmuir, 2014, 30, 10886-10898.	3.5	88
26	Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biology and Medicine, 2014, 11, 44-55.	3.0	88
27	New Generation of Liposomal Drugs for Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 537-552.	1.7	83
28	Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy. Journal of Controlled Release, 2016, 228, 150-158.	9.9	83
29	Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 929-937.	2.5	78
30	Biodegradable Janus Nanoparticles for Local Pulmonary Delivery of Hydrophilic and Hydrophobic Molecules to the Lungs. Langmuir, 2014, 30, 12941-12949.	3.5	78
31	Targeted proapoptotic LHRH-BH3 peptide. Pharmaceutical Research, 2003, 20, 889-896.	3.5	73
32	Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 335-344.	4.3	72
33	Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opinion on Drug Delivery, 2021, 18, 205-227.	5.0	72
34	Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics, 2021, 13, 2049.	4.5	64
35	Labile Catalytic Packaging of DNA/siRNA: Control of Gold Nanoparticles â€œoutâ€•of DNA/siRNA Complexes. ACS Nano, 2010, 4, 3679-3688.	14.6	61
36	Targeted Proapoptotic Anticancer Drug Delivery System. Molecular Pharmaceutics, 2007, 4, 668-678.	4.6	60

#	Article	IF	Citations
37	Precision targeted therapy of ovarian cancer. Journal of Controlled Release, 2016, 243, 250-268.	9.9	59
38	Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1Î± Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor. Clinical Cancer Research, 2008, 14, 3607-3616.	7.0	54
39	Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Current Drug Discovery Technologies, 2013, 10, 8-15.	1.2	53
40	Soluble polymer conjugates for drug delivery. Drug Discovery Today: Technologies, 2005, 2, 15-20.	4.0	52
41	Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1983-1992.	3.3	52
42	Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. Journal of Controlled Release, 2020, 326, 222-244.	9.9	52
43	LHRH-Targeted Drug Delivery Systems for Cancer Therapy. Mini-Reviews in Medicinal Chemistry, 2017, 17, 258-267.	2.4	49
44	Multifunctional Tumor-Targeted Polymer-Peptide-Drug Delivery System for Treatment of Primary and Metastatic Cancers. Pharmaceutical Research, 2010, 27, 2296-2306.	3.5	47
45	LHRH-Targeted Nanoparticles for Cancer Therapeutics. Methods in Molecular Biology, 2010, 624, 281-294.	0.9	44
46	Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine, 2012, 7, 185-197.	3.3	43
47	Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy. Pharmaceutical Research, 2014, 31, 3487-3502.	3.5	43
48	Nanotechnology approaches for inhalation treatment of fibrosis. Journal of Drug Targeting, 2013, 21, 914-925.	4.4	39
49	Antibodies and Peptides in Cancer Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2006, 23, 401-436.	2.2	35
50	Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value. Advanced Drug Delivery Reviews, 2017, 113, 122-140.	13.7	33
51	HPMA copolymerâ€“anticancer drugâ€“OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound Adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 49, 11-15.	4.3	32
52	HPMA copolymers for modulating cellular signaling and overcoming multidrug resistanceâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 192-202.	13.7	29
53	Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the â€˜Undruggableâ€™ MYC in Pancreatic Cancer. Trends in Pharmacological Sciences, 2020, 41, 684-686.	8.7	29
54	Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations. Pharmaceutics, 2021, 13, 1063.	4.5	29

#	Article	IF	Citations
55	Poly(propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function. International Journal of Nanotechnology, 2011, 8, 36.	0.2	28
56	Delivery of antisense oligonucleotides using poly(alkylene oxide)â€“poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes. Journal of Controlled Release, 2014, 194, 103-112.	9.9	28
57	Prevention of paclitaxel-induced neuropathy by formulation approach. Journal of Controlled Release, 2019, 303, 109-116.	9.9	28
58	Characterization of a novel hydroxypropyl methylcellulose (HPMC) direct compression grade excipient for pharmaceutical tablets. International Journal of Pharmaceutics, 2020, 583, 119343.	5.2	20
59	Functionalized Mesoporous Silica Nanoparticles for Glucoseâ€•and pHâ€Stimulated Release of Insulin. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2014, 640, 616-623.	1.2	18
60	Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage. Drug Delivery and Translational Research, 2011, 1, 13-24.	5.8	16
61	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Advanced Therapeutics, 2021, 4, 2000203.	3.2	16
62	Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutationâ€”Positive Lung Cancer Cells. Pharmaceutics, 2020, 12, 939.	4.5	15
63	Evaluation of AffinisolÂ® HPMC polymers for direct compression process applications. Journal of Drug Delivery Science and Technology, 2018, 47, 461-467.	3.0	14
64	Nanotechnology and drug resistance. Advanced Drug Delivery Reviews, 2013, 65, 1665-1666.	13.7	11
65	Loss-in-weight feeding, powder flow and electrostatic evaluation for direct compression hydroxypropyl methylcellulose (HPMC) to support continuous manufacturing. International Journal of Pharmaceutics, 2021, 596, 120259.	5.2	11
66	Nanostructured TiO2 Catalyzed Oxidations of Caffeine and Isocaffeine and Their Cytotoxicity and Genotoxicity Towards Ovarian Cancer Cells. BioNanoScience, 2014, 4, 27-36.	3.5	9
67	Remediation of Cellular Hypoxic Damage by Pharmacological Agents. Current Pharmaceutical Design, 2005, 11, 3185-3199.	1.9	6
68	Receptor Mediated Delivery Systems for Cancer Therapeutics. , 2012, , 329-355.		6
69	Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget, 2018, 9, 33249-33257.	1.8	6
70	On the plasticizing properties of divalproex sodium: physicochemical and spectroscopic characterization studies. Pharmaceutical Development and Technology, 2019, 24, 455-464.	2.4	4
71	Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 1381-1392.	4.1	0